When Ozempic And Wegovy Fail To Work- Why GLP-1 Drugs Aren’t The Magic Bullet For Everyone
Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.
Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.
While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:
1. Genetic and Hormonal Variability
Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.
2. Underlying Medical Conditions
Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.
3. Unrealistic Expectations
Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.
For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.
For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.
When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:
For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.
While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.
Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.
It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.
For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.
Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.
This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.
While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.
The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.
Credits: Canva
Sepsis that happened by a lick from a pet dog led to a woman losing all four of her limbs. Health and Me had previously reported that a Birmingham based woman, 56-year-old pharmacy worker Manjit Sangha caught sepsis from the lick of her pet dog. She spent her night in coma in the hospital and had to lose all her limbs. This happened because bacteria from dog's lick entered her body through a cut or a scratch. This led to sepsis, where the immune system's reaction to infection damaged the body's own tissues and organs.
This has brought a lot of attention on what sepsis is and what are the symptoms one must be aware of. As per the Sepsis Alliance, one must know about TIME to be aware of sepsis.
TIME stands for temperature, infection, mental decline and extremely ill. If you notice these symptoms, rush to the hospital.
Your body temperature normally stays steady at about 98.6°F (37°C), with small changes based on activity, surroundings, and time of day. A reading of 100°F (37.7°C) or higher is considered a fever. During infection, the body often heats up to help fight germs. However, some people experience an unusual drop in temperature instead. Because of this, both a spike and a fall in temperature can be warning signs of sepsis.
When an infection stays in one area, its symptoms usually match the site involved. A urinary tract infection may cause burning while urinating or frequent urges, pneumonia can bring cough and chest pain, and an infected cut may show redness or pus.
If the infection spreads through the body, broader symptoms like fever, tiredness, and body aches can appear. In some cases, an infection may not cause obvious symptoms at all. This is especially important to remember after surgery, medical procedures, skin injuries, or close contact with someone who is sick.
Sepsis can also alter how the brain functions. Some people, particularly older adults, may not develop the usual infection symptoms. Instead, they might suddenly become confused or show a sharp worsening of existing dementia. Marked drowsiness or unusual sleepiness is another common sign.
Many sepsis survivors recall feeling sicker than ever before. They describe overwhelming symptoms such as the most severe sore throat or abdominal pain they had experienced, along with a frightening sense that they might not survive.
| A Child Who | Child under 5 (Infant) Who |
| Feels abnormally cold to touch | Is not eating |
| Looks mottled, bluish or has very pale skin | Is vomiting repeatedly |
| Has a rash that does not fade when you press it | Has not urinated in 12 hours |
| Is breathing very fast | |
| Has a convulsion | |
| Is very lethargic or is facing difficulty in waking up |
Credits: SWNS (Tianna Moon)
Mounjaro, a popular weight loss drug that helped many lose weight, however, in this one case, a woman, who was on the same drug noticed something different. While she lost weight, she noticed that her breasts continued to grow. The 30-year-old Tianna Moon of East Anglia, a region in eastern England first realized something was not normal with her chest in 2024. This was when she started to use Mounjaro.
She was losing weight, but her breasts continued to grow. This is when Moon's doctor diagnosed her with a rare disease call gigantomastia, which causes breast tissue to grow rapidly and in excess.
Also Read: 15 States Sue Trump Administration Over Revised Vaccine Schedule
Moon said that the doctors had thought that she had macromastia, a less severe, however, a similar condition. "But when I broke down medical history, the weight loss on Mounjaro and the increased growth and side effects, he was point-blank like, 'This is gigantomastia'," she said.
Moon also told that her breasts currently weight 39 lbs, which is approximately 20 per cent of her overall body weight.
Moon also said that while her large breasts are "normal" at this point in her life, she said the rare condition still comes with challenges.
"The side effects are having numb arms quite a lot and having quite severe indentations on my shoulders. I have some light scarring under my breasts where bras have rubbed and ripped the skin open."
She also said that laying on her back is something she cannot do for a long time, as it restricts the amount of airflow she can get in. She also said that when she goes out she tries to make her breasts look smaller than they are and strap them up. "I [still] get stares and double takes."
Also Read: Wegovy And Ozempic Will Cost Less In 2027, Novo Nordisk Slashes Weight Loss Drugs Prices By Half
As per Cleveland Clinic, it is a rare condition where your breasts become excessively large. It can also cause pain, infection, discomfort and issues with body image. It is also known as breast hypertrophy where one experiences rapid and disproportionate breast growth. The speed with which the breasts grow could vary depending on the person. It could take a few weeks to over several years. The tissue is almost never benign.
Moon is now considering a breast reduction surgery. She has for now set up an account on OnlyFans. “I might as well try and reap the benefits of my medical condition rather than the negatives," she said.
Credit: X
The recent launch of the indigenous Td vaccine in India by Union Health Minister JP Nadda will boost immunity and reduce the risk of tetanus and diphtheria in children and adults, said health experts.
Union Health Minister JP Nadda formally launched the indigenously manufactured Td vaccine in Himachal Pradesh last week.
With the launch, the Tetanus Toxoid (TT) vaccine has been replaced with the Tetanus and adult diphtheria (Td) vaccine in India’s immunization program for all age groups, including pregnant women.
The move comes amid increasing numbers of cases of diphtheria amongst older age groups. Tetanus and diphtheria can lead to hospitalizations or even cause death. The Td vaccine will help to decrease diphtheria outbreaks.
“In keeping with global practice, India has shifted from TT, which covers for tetanus, to Td, which covers for both tetanus and diphtheria. This vaccine is indigenously manufactured and is expected to significantly reduce the risk of both these diseases in older children as well as adults,” Dr. Rajeev Jayadevan, Ex-President of IMA Cochin and Convener of the Research Cell, Kerala, told HealthandMe.
The Td vaccine, indigenously manufactured at the Central Research Institute (CRI), Kasauli in Himachal Pradesh, is a combination of tetanus and diphtheria with a lower concentration of diphtheria antigen (d), and is recommended for older children and adults.
The use of Td, instead of TT, is recommended during pregnancy to protect against maternal and neonatal tetanus and diphtheria during prenatal care.
Vaccination during pregnancy also serves to boost immunity and increase the duration of protection in pregnant women who have not received the full set of recommended booster doses.
The Td is a safe vaccine, and 133 countries are currently using it.
The Health Ministry, in a statement, said that the Central Research Institute will supply 55 lakh doses to the UIP by April 2026, with production expected to scale up progressively in subsequent years to further strengthen the Universal Immunization Program in India.
“India’s indigenous Td vaccine rollout marks a significant milestone in strengthening the nation’s immunization program by enhancing self-reliance, affordability, and supply stability,” Dr. Neha Rastogi, Senior Consultant - Infectious Diseases, Fortis Gurugram, told HealthandMe.
“Locally produced vaccines reduce dependency on imports, ensuring uninterrupted protection for adolescents and adults against tetanus and diphtheria. This initiative supports wider coverage, faster distribution to remote regions, and improved public health preparedness,” she added.
As per the National Health Profile 2022, India has reported 1,586 cases and 22 deaths due to diphtheria in 2020, and 3,677 cases and 47 deaths in 2021.
Around 10 Indian states report the majority (84 per cent) of the cases.
As of 21 June 2024, Orissa has also reported six deaths and 21 suspected diphtheria cases. There has been more than 90 percent coverage of diphtheria vaccination in birth cohorts since 2014, but gaps in booster dose coverage are widely prevalent.
Plugging of gaps in the routine immunization, coupled with inclusion of booster doses in the national data on diphtheria vaccination, is the need of the hour.
“Diphtheria is one of the most dangerous infectious diseases known to man; it spreads easily through the respiratory route. It can cause death due to the bacterial toxin affecting the heart (Myocarditis). It is vaccine-preventable, but the immunity fades over time,” Dr. Jayadevan said.
Therefore, the Td booster shots at ages 10 and 16 are essential to maintain protection. Similarly, pregnant women should receive two doses to protect both mother and child.
Given the recent outbreaks of diphtheria in India and elsewhere, this transition is a public health priority, the expert said.
© 2024 Bennett, Coleman & Company Limited